[Expression of MUC1 gene and MDR1 gene in non-M3 subtype acute leukemia and their correlations to clinical treatment efficacy].
OBJECTIVE
Mucin 1 (MUC1) gene is expressed in various tumors, and overexpressed in acute leukemia. This study was to evaluate the expression of MUC1 gene and multidrug-resistance protein-1 (MDR1) gene in non-M3 subtype acute leukemia and their correlations to clinical treatment efficacy.


METHODS
The expression of MUC1 and MDR1 genes were measured in 34 patients with non-M3 subtype acute leukemia by reverse transcription-polymerase chain reaction (RT-PCR); their correlations to clinical treatment efficacy were observed.


RESULTS
The positive rate of MUC1 gene in the 34 patients was 50.0%, and the positive rate of MDR1 gene was 29.4%. The positive rate of MDR1 was significantly higher in MUC1-positive patients than in MUC1-negative patients (52.9% vs. 5.9%, P=0.003). Complete remission (CR) rate was significantly higher in MUC1-negative patients than in MUC1-positive patients (94.1% vs. 52.9%, P<0.01). CR rate was significantly higher in MDR1-negative patients than in MDR1-positive patients (91.7% vs. 50.0%, P<0.05). In 9 patients with positive expression of both MUC1 and MDR1, the CR rate was 55.6%; while in 16 patients with negative expression of both MUC1 and MDR1, the CR rate was 100%.


CONCLUSIONS
The non-M3 subtype acute leukemia patients with positive expression of MUC1 have high positive rate of MDR1. The patients with negative expression of both MUC1 and MDR1 have high CR. Co-detection of MUC1 gene and MDR1 gene can predict treatment efficacy on non-M3 subtype acute leukemia.
Li
Guo-Wei
GW
Department of Hematology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, P. R. China.
Wang
Dong-Ning
DN
Lin
Dong-Jun
DJ
Li
Xu-Dong
XD
Lin
Gui-Zhen
GZ
He
Yi
Y
Lin
Qu
Q
Huang
Ren-Wei
RW
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics / Q000378:metabolism*; D000293:Adolescent; D000328:Adult; D000951:Antigens, Neoplasm / Q000235:genetics / Q000378:metabolism*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy / Q000378:metabolism; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000378:metabolism*; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D018396:Mucin-1; D009077:Mucins / Q000235:genetics / Q000378:metabolism*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000378:metabolism*; D012074:Remission Induction; D016896:Treatment Outcome
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000951:Antigens, Neoplasm; C060192:MUC1 protein, human; D018396:Mucin-1; D009077:Mucins